Roche: hemophilia drug Hemlibra approved in Taiwan
(CercleFinance.com) - Roche's Japanese unit Chugai has obtained approval from Taiwanese regulators for Hemlibra for routine prophylaxis of bleeding episodes in patients with hemophilia A.
Chugai's bispecific monoclonal antibody has received regulatory approval for patients with hemophilia A with factor VIII inhibitors, with once weekly subcutaneous injection, the company said on Tuesday.
Copyright (c) 2018 CercleFinance.com. All rights reserved.
Chugai's bispecific monoclonal antibody has received regulatory approval for patients with hemophilia A with factor VIII inhibitors, with once weekly subcutaneous injection, the company said on Tuesday.
Copyright (c) 2018 CercleFinance.com. All rights reserved.